Oric Pharmaceuticals, Inc. $ORIC Holdings Cut by Sectoral Asset Management Inc.

Sectoral Asset Management Inc. lowered its holdings in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 93.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,480 shares of the company’s stock after selling 306,175 shares during the period. Sectoral Asset Management Inc.’s holdings in Oric Pharmaceuticals were worth $184,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Blue Owl Capital Holdings LP bought a new position in Oric Pharmaceuticals in the fourth quarter worth about $4,213,000. Nano Cap New Millennium Growth Fund L P bought a new position in Oric Pharmaceuticals in the fourth quarter worth about $123,000. ProShare Advisors LLC lifted its holdings in Oric Pharmaceuticals by 22.5% in the fourth quarter. ProShare Advisors LLC now owns 16,392 shares of the company’s stock worth $134,000 after acquiring an additional 3,009 shares during the last quarter. UBS Group AG lifted its holdings in Oric Pharmaceuticals by 116.6% in the fourth quarter. UBS Group AG now owns 734,858 shares of the company’s stock worth $6,011,000 after acquiring an additional 395,622 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in Oric Pharmaceuticals by 21.0% in the fourth quarter. Arizona State Retirement System now owns 12,163 shares of the company’s stock worth $99,000 after acquiring an additional 2,107 shares during the last quarter. Institutional investors own 95.05% of the company’s stock.

Insider Activity at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 52,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total transaction of $702,520.00. Following the transaction, the chief financial officer owned 68,148 shares in the company, valued at $920,679.48. This trade represents a 43.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.70% of the stock is owned by corporate insiders.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ ORIC opened at $8.32 on Monday. The stock has a 50 day simple moving average of $10.04 and a 200-day simple moving average of $10.59. The company has a market cap of $861.29 million, a PE ratio of -5.78 and a beta of 1.11. Oric Pharmaceuticals, Inc. has a 12-month low of $5.51 and a 12-month high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.03). Sell-side analysts forecast that Oric Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ORIC shares. Wall Street Zen cut shares of Oric Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Oric Pharmaceuticals in a report on Thursday, April 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Oric Pharmaceuticals in a report on Friday. Oppenheimer reissued an “outperform” rating and issued a $15.00 target price on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Tuesday, April 21st. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.36.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.